10-Q: Acro Biomedical Faces Severe Going Concern Doubts

Acro Biomedical reports no revenue, continued losses, and significant going concern issues for Q2 2024, relying solely on related party advances.

Summary

• Reported no revenue for the three and six months ended June 30, 2024, consistent with no sales since December 31, 2022.
• Incurred a net loss of $10,143 for the three months ended June 30, 2024, and $21,395 for the six months ended June 30, 2024.
• Operating expenses significantly decreased to $9,086 for the three months and $19,384 for the six months ended June 30, 2024, primarily due to the full amortization of deferred stock compensation and expiration of consultant contracts in 2023.
• Cash balance was $926 as of June 30, 2024, a slight increase from $376 at December 31, 2023, primarily funded by advances from related parties.
• Working capital deficiency worsened to $(307,103) at June 30, 2024, from $(286,949) at December 31, 2023.
• The company's common stock is listed on the OTC Market Group's Expert Market, meaning it is not eligible for proprietary broker-dealer quotes and has no market makers, restricting public viewing of quotations.
• Research and development efforts for a cordyceps-infused chicken feed did not result in any marketable products, and consultant contracts expired in May and August 2023.
• The company has no full-time employees; the Chief Executive Officer and Chief Financial Officer serves part-time without compensation.

Sentiment

Score: 1

Explanation: The company faces severe existential challenges, including no revenue, persistent losses, critical going concern doubts, and an inability to access capital markets. Its R&D efforts have failed, and it relies entirely on related party funding, indicating an extremely negative outlook.

Positives

• Operating expenses decreased significantly from $7,198,266 in the first six months of 2023 to $19,384 in the first six months of 2024, primarily due to the cessation of stock-based compensation and consultant fees.

Negatives

• No revenue generated for the three and six months ended June 30, 2024, continuing a trend of no sales since December 31, 2022.
• Incurred net losses of $10,143 and $21,395 for the three and six months ended June 30, 2024, respectively.
• Minimal cash balance of $926 as of June 30, 2024, and a worsening working capital deficiency of $(307,103).
• Substantial doubt exists about the company's ability to continue as a going concern due to lack of revenue, operating losses, negative cash flow, and limited access to capital markets.
• Research and development efforts have not yielded any marketable products, and the company has no current orders for products.
• Common stock trades on the OTC Market Group's Expert Market, severely limiting liquidity and investor access.
• The company is delinquent in its filings with the Securities and Exchange Commission, further hindering its ability to raise funds.
• Reliance on advances from a minority stockholder and an officer for funding, with no assurance of continued support.

Risks

• Substantial doubt about the ability to continue as a going concern due to minimal cash, no revenue, operating losses, and negative cash flow.
• Inability to raise necessary financing through debt or equity securities due to financial condition, lack of sales, and Expert Market listing.
• Difficulty in increasing customer base and supply chain, and inability to increase gross margins.
• Challenges in hiring and retaining qualified research and development, marketing, and administrative personnel.
• Failure to develop marketable products or generate significant revenue and profits in the future.
• Potential impact of political instability in Hong Kong on future sales, as past customers were Hong Kong-based and sold into the PRC.
• Exposure to inflationary pressures, supply chain disruptions, and increased tariffs, which could affect costs and pricing.
• Material weaknesses in internal controls over financial reporting, including absence of segregation of duties and reliance on a single part-time, unpaid CEO/CFO without an accounting background.
• Delinquency in SEC filings, which restricts access to capital markets.

Future Outlook

The company cannot assure that it will be able to develop any products or generate revenue or profits in the future. It anticipates incurring marketing and other expenses without assurance of significant revenue. The ability to raise funds through equity financing is uncertain due to financial condition, lack of sales, and the common stock being traded on the OTC Market Group's Expert Market. The company will likely continue to rely on loans from stockholders or related parties and may use equity-based compensation, though the Expert Market status may deter potential employees or consultants.

Management Comments

• "We cannot assure you that we can or will develop any products or generate revenue or profits in the future."
• "We cannot assure you that he [minority stockholder] will continue to provide funding for us."
• "Our disclosure controls were not effective as of June 30, 2024, due to the inadequacy of our internal controls over financial reporting, our sole employee being our chief executive and financial officer and our limited internal audit function."
• "The lack of any separation of duties, with the same person, who is our only employee who serves as both chief executive officer and chief financial officer, who is our sole director and who does not have an accounting background and serves on a part-time basis, makes it unlikely that we will be able to implement effective internal controls over financial reporting in the near future."

Industry Context

The company operates in the traditional Chinese medicine and nutritional products sector, specifically focusing on cordyceps-related products. Its past sales were heavily reliant on customers selling into China, making it vulnerable to Chinese government policies like the Zero COVID policy and broader economic slowdowns. The failure of its R&D efforts for a cordyceps-infused chicken feed highlights the challenges of product development and market entry in this competitive space. The company's current state of no revenue and significant operational issues places it far behind industry peers who are actively developing, marketing, and selling products.

Comparison to Industry Standards

• The company's complete lack of revenue since December 31, 2022, is significantly below industry standards for publicly traded companies in the nutritional products or biomedical sectors, which typically demonstrate ongoing sales and growth.
• The substantial doubt about the company's ability to continue as a going concern is a critical deviation from the financial stability expected of comparable companies.
• The failure of research and development efforts to yield marketable products, such as the cordyceps-infused chicken feed, contrasts sharply with successful product pipelines and innovation seen in established biomedical or health supplement companies.
• Operating on the OTC Market Group's Expert Market, with no market makers and restricted public viewing of quotes, is a severe disadvantage compared to companies listed on major exchanges (e.g., NASDAQ, NYSE) or even more liquid OTC markets, which offer greater investor access and liquidity.
• The reliance on a single minority stockholder for operational funding is highly unusual and unsustainable compared to diversified funding sources (e.g., institutional investors, commercial loans, public offerings) typically utilized by industry peers.
• The acknowledged material weaknesses in internal controls and the lack of segregation of duties, with the CEO/CFO being the sole employee, fall far below corporate governance and financial reporting standards expected of any public company, let alone those in the biomedical sector where regulatory compliance is paramount.

Corporate Governance

Related Party Transactions

• A minority stockholder advanced $1,000 and paid expenses of $19,392 on behalf of the company during the six months ended June 30, 2024.
• As of June 30, 2024, the company owed $108,088 to the minority stockholder for non-interest-bearing advances and paid expenses.
• As of June 30, 2024, the company owed $1,100 to its chief executive officer for non-interest-bearing advances and paid expenses.
• Imputed interest on related party loans amounted to $2,011 for the six months ended June 30, 2024.
• The minority stockholder paid the security deposit and annual rental for the Hong Kong storage facility lease.

Stakeholder Impact

• Shareholders face significant dilution risk if equity financing is pursued, and the Expert Market listing severely limits liquidity and transparency for their investment.
• The company's ability to continue as a going concern is in substantial doubt, posing a risk of total loss for investors.
• The sole employee, the CEO/CFO, works part-time without compensation, indicating a lack of dedicated management resources.
• Past customers experienced financial losses due to COVID-19, leading to a $480,000 accounts receivable write-off in 2023, and there are no current orders.
• Creditors, primarily related parties, bear the risk of non-repayment given the company's financial distress and going concern issues.

Next Steps

• Generate revenue from products (currently no orders).
• Seek to raise funds in the equity market or through loan facilities.
• Increase customer base and supply chain.
• Develop new products or market existing ones more effectively.
• Address material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

The company presents an extremely high-risk profile with no revenue, persistent operating losses, and a severe working capital deficiency. The explicit 'going concern' doubt, reliance on related party funding, and the stock's listing on the illiquid OTC Expert Market indicate a fundamental lack of a viable business model and access to capital. The failure of R&D efforts and significant internal control weaknesses further compound these issues. A seasoned investor would recognize the substantial risk of capital loss and recommend a strong sell.

Keywords

Cordyceps, Biomedical, Nutritional Products, SEC Filing, 10-Q, Going Concern, OTC Expert Market, Financial Reporting, Related Party Transactions, Research and Development